Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Home Print this page Email this page
Users Online:: 1204
Year : 2009  |  Volume : 12  |  Issue : 4  |  Page : 143-147

Effects of stavudine - Based antiretroviral therapy on distal symmetrical polyneuropathy in HIV/AIDS patients: A preliminary report

1 Clinical Pharmacology Unit, Department of Medicine, Ahmadu Bello University Teaching Hospital, Shika, Zaria, Nigeria
2 University College Hospital, Ibadan, Nigeria

Correspondence Address:
O R Obiako
Clinical Pharmacology Unit, Department of Medicine, Ahmadu Bello University Teaching Hospital, Shika, Zaria
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Background: Distal symmetrical polyneuropathy is a debilitating illness seen in more than 30% of antiretroviral naive Acquired immune deficiency syndrome patients and 4% of those on stavudine and didanosine, current first-line antiretroviral drugs in Nigeria. This study determines the influence of stavudine-based antiretroviral therapy on: Distal symmetrical polyneuropathy in Human immunodeficiency virus/acquired immune deficiency syndrome patients. Methods: We carried out prospective cross-sectional study of 220 antiretroviral-naΟve Human immunodeficiency virus/acquired immune deficiency syndrome adult patients referred to the antiretroviral human immuno deficiency virus care and treatment clinic in Ahmadu Bello University Teaching Hospital, Shika Zaria between August 2005 and May 2006 They were evaluated using a protocol modified from the subjective peripheral neuropathy screen and the Leeds assessment of neuropathic symptoms and signs pain score. Each subject was then put on capsule stavudine 30/40 mg (based on body weight) twice daily + tablet lamivudine 150 mg twice daily + tablet nevirapine 200 mg (daily for 2 weeks and twice daily thereafter). After 3 months they were re-evaluated using same baseline protocol. Subjects with diabetes, renal or liver disease, prior ART-experience, and on antituberculous therapy were excluded from the study. Results: After 3 months of antiretroviral therapy the median symptoms and signs was significantly reduced from 31.4% (range 3.2% to 42.3%) to 18.2% (range 0.5% to 25.5%) and 18.2% (range 0.5% to 84.1%) to 5.9% (range 0.0% to 83.6%), respectively. Conclusion: Significant reductions in the frequencies of DSP symptoms and signs were observed with stavudine-based ART. Our findings as well as the long term neurotoxic effects of this relatively affordable regimen in a resource depleted setting needs to be confirmed in a larger scale and multi-centered study.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded64    
    Comments [Add]    

Recommend this journal